Serogroup B Meningococcal Meningitis

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Serogroup B Meningococcal Meningitis trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT06832514

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

Sexual differences are a well-established source of biological variation in immune system functioning, with men often displaying lower adaptive immune responses…

Belgium250 participantsStarted 2025-01-31

Treatment: Serogroup B meningococal vaccine

All recent trials (22 shown)

CompletedPhase 4

NCT01593514

Understanding the Immune Response to Two Different Meningitis Vaccines

The bacterium (germ) Neisseria meningitidis causes meningitis and blood poisoning. N meningitidis is classified into different serogroups (types), based on its…

United Kingdom20 participantsStarted 2012-12

Treatment: MenACWY-CRM conjugate vaccine (Menveo, Novartis), MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)

Active — Not RecruitingPhase 4

NCT06113198

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants…

The purpose of this study is to assess the safety and immune responses of rMenB+OMV NZ vaccine when administered to healthy infants from 2 months in the Republi…

South Korea50 participantsStarted 2023-11-10

Treatment:

Serogroup B Meningococcal Meningitis

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

All recent trials (22 shown)

Understanding the Immune Response to Two Different Meningitis Vaccines

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

All recent trials (22 shown)

Understanding the Immune Response to Two Different Meningitis Vaccines

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants…

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Heal…

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningoc…

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To…

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When…

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When G…

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Investigating the Immune Response to 4CMenB in Infants

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With…

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Ag…

Safety Surveillance of MenACWY-CRM Vaccine in Children

Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pert…

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1…

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Safety of MenACWY-CRM Vaccination in Adolescents